References(62)
[1]
Kawczyk-Krupka, A.; Bugaj, A. M.; Latos, W.; Zaremba, K.; Sieroń, A. Photodynamic therapy in treatment of cutaneous and choroidal melanoma. Photodiagnosis Photodyn. Ther. 2013, 10, 503-509.
[2]
Domingues, B.; Lopes, J. M.; Soares, P.; Pópulo, H. Melanoma treatment in review. Immunotargets Ther. 2018, 7, 35-49.
[3]
Luo, L. J.; Shu, R.; Wu, A. G. Nanomaterial-based cancer immunotherapy. J. Mater. Chem. B 2017, 5, 5517-5531.
[4]
Zhang, Y.; Bush, X.; Yan, B. F.; Chen, J. A. Gemcitabine nanoparticles promote antitumor immunity against melanoma. Biomaterials 2019, 189, 48-59.
[5]
Zeng, Z.; Wei, Z. L.; Ma, L. M.; Xu, Y.; Xing, Z. H.; Niu, H.; Wang, H. B.; Huang, W. pH-responsive nanoparticles based on ibuprofen prodrug as drug carriers for inhibition of primary tumor growth and Metastasis. J. Mater. Chem. B 2017, 5, 6860-6868.
[6]
Li, L.; Song, L. J.; Yang, X.; Li, X.; Wu, Y. Z.; He, T.; Wang, N.; Yang, S. L. X.; Zeng, Y.; Yang, L. et al. Multifunctional “core-shell” nanoparticles-based gene delivery for treatment of aggressive melanoma. Biomaterials 2016, 111, 124-137.
[7]
Fraix, A.; Manet, I.; Ballestri, M.; Guerrini, A.; Dambruoso, P.; Sotgiu, G.; Varchi, G.; Camerin, M.; Coppellotti, O.; Sortino, S. Polymer nanoparticles with electrostatically loaded multicargo for combined cancer phototherapy. J. Mater. Chem. B 2015, 3, 3001-3010.
[8]
Su, H.; Wang, Y. F.; Gu, Y. L.; Bowman, L.; Zhao, J. S.; Ding, M. Potential applications and human biosafety of nanomaterials used in nanomedicine. J. Appl. Toxicol. 2018, 38, 3-24.
[9]
Xu, Z. L.; Liu, C. S.; Wei, J.; Sun, J. Effects of four types of hydroxyapatite nanoparticles with different nanocrystal morphologies and sizes on apoptosis in rat osteoblasts. J. Appl. Toxicol. 2012, 32, 429-435.
[10]
Yuan, Y.; Liu, C. S.; Qian, J. C.; Wang, J.; Zhang, Y. Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells. Biomaterials 2010, 31, 730-740.
[11]
Szcześ, A.; Hołysz, L.; Chibowski, E. Synthesis of hydroxyapatite for biomedical applications. Adv. Colloid Interface Sci. 2017, 249, 321-330.
[12]
Lee, W. H.; Loo, C. Y.; Rohanizadeh, R. Functionalizing the surface of hydroxyapatite drug carrier with carboxylic acid groups to modulate the loading and release of curcumin nanoparticles. Mater. Sci. Eng. C 2019, 99, 929-939.
[13]
Farokhi, M.; Mottaghitalab, F.; Samani, S.; Shokrgozar, M. A.; Kundu, S. C.; Reis, R. L.; Fatahi, Y.; Kaplan, D. L. Silk fibroin/hydroxyapatite composites for bone tissue engineering. Biotechnol. Adv. 2018, 36, 68-91.
[14]
Aoki, H.; Ohgaki, M.; Kano, S. Effects of Adriacin-absorbing hydroxyapatite-sol on Ca-9 cell growth. Rep. Inst. Med. Dent. Eng. 1993, 27, 39-44.
[15]
Jin, J.; Zuo, G. F.; Xiong, G. Y.; Luo, H. L.; Li, Q. P.; Ma, C. Y.; Li, D. Y.; Gu, F.; Ma, Y. J.; Wan, Y. Z. The inhibition of lamellar hydroxyapatite and lamellar magnetic hydroxyapatite on the migration and adhesion of breast cancer cells. J. Mater. Sci.: Mater. Med. 2014, 25, 1025-1031.
[16]
Zhao, H.; Wu, C. H.; Gao, D.; Chen, S. P.; Zhu, Y. D.; Sun, J.; Luo, H. R.; Yu, K.; Fan, H. S.; Zhang, X. D. Antitumor effect by hydroxyapatite nanospheres: Activation of mitochondria-dependent apoptosis and negative regulation of phosphatidylinositol-3-Kinase/Protein Kinase B pathway. ACS Nano 2018, 12, 7838-7854.
[17]
Tang, W.; Yuan, Y.; Liu, C. S.; Wu, Y. Q.; Lu, X.; Qian, J. C. Differential cytotoxicity and particle action of hydroxyapatite nanoparticles in human cancer cells. Nanomedicine 2014, 9, 397-412.
[18]
Meena, R.; Kesari, K. K.; Rani, M.; Paulraj, R. Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human breast cancer cells (MCF-7). J. Nanopart. Res. 2012, 14, 712.
[19]
Han, Y. C.; Li, S. P.; Cao, X. Y.; Yuan, L.; Wang, Y. F.; Yin, Y. X.; Qiu, T.; Dai, H. L.; Wang, X. Y. Different inhibitory effect and mechanism of hydroxyapatite nanoparticles on normal cells and cancer cells in vitro and in vivo. Sci. Rep. 2014, 4, 7134.
[20]
Zhang, H. F.; Qing, F. Z.; Zhao, H.; Fan, H. S.; Liu, M.; Zhang, X. D. Cellular internalization of rod-like nano hydroxyapatite particles and their size and dose-dependent effects on pre-osteoblasts. J. Mater. Chem. B 2017, 5, 1205-1217.
[21]
Qing, F. Z.; Wang, Z.; Hong, Y. L.; Liu, M.; Guo, B.; Luo, H. R.; Zhang, X. D. Selective effects of hydroxyapatite nanoparticles on osteosarcoma cells and osteoblasts. J. Mater. Sci.: Mater. Med. 2012, 23, 2245-2251.
[22]
Zhang, K.; Zhou, Y.; Xiao, C.; Zhao, W. L.; Wu, H. F.; Tang, J. Q.; Li, Z. T.; Yu, S.; Li, X. F.; Min, L. et al. Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect. Sci. Adv. 2019, 5, eaax6946.
[23]
Guo, B.; Li, B.; Wang, X. L.; Zhang, M. X.; Yan, N. H.; Zhang, X. D. Influence of different hydroxyapatite particles on the behavior of highly malignant melanoma cells. Key Eng. Mater. 2007, 330-332, 279-282.
[24]
Li, B.; Guo, B.; Fan, H. S.; Zhang, X. D. Preparation of nano-hydroxyapatite particles with different morphology and their response to highly malignant melanoma cells in vitro. Appl. Surf. Sci. 2008, 255, 357-360.
[25]
Devanand Venkatasubbu, G.; Ramasamy, S.; Avadhani, G. S.; Palanikumar, L.; Kumar, J. Size-mediated cytotoxicity of nanocrystalline titanium dioxide, pure and zinc-doped hydroxyapatite nanoparticles in human hepatoma cells. J. Nanopart. Res. 2012, 14, 819.
[26]
Tay, C. Y.; Fang, W. R.; Setyawati, M. I.; Chia, S. L.; Tan, K. S.; Hong, C. H. L.; Leong, D. T. Nano-hydroxyapatite and nano-titanium dioxide exhibit different subcellular distribution and apoptotic profile in human oral epithelium. ACS Appl. Mater. Interfaces 2014, 6, 6248-6256.
[27]
Shen, L.; Liu, L. B.; Yang, Z. Y.; Jiang, N. Identification of genes and signaling pathways associated with squamous cell carcinoma by bioinformatics analysis. Oncol. Lett. 2016, 11, 1382-1390.
[28]
Dower, C. M.; Wills, C. A.; Frisch, S. M.; Wang, H. G. Mechanisms and context underlying the role of autophagy in cancer metastasis. Autophagy 2018, 14, 1110-1128.
[29]
Ma, X. H.; Wu, Y. T.; Zhang, T.; Song, H.; Jv, H. Y.; Guo, W.; Ren, G. X. Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases. J. Cancer 2017, 8, 3828-3837.
[30]
Liu, L. N.; Zhang, H. M.; Shi, L.; Zhang, W. J.; Yuan, J. L.; Chen, X.; Liu, J. J.; Zhang, Y.; Wang, Z. P. Inhibition of Rac1 activity induces G1/S phase arrest through the GSK3/cyclin D1 pathway in human cancer cells. Oncol. Rep. 2014, 32, 1395-1400.
[31]
Azevedo-Barbosa, H.; Ferreira-Silva, G. Á.; Silva, C. F.; De Souza, T. B.; Dias, D. F.; De Paula, A. C. C.; Ionta, M.; Carvalho, D. T. Phenylpropanoid-based sulfonamide promotes cyclin D1 and cyclin E down-regulation and induces cell cycle arrest at G1/S transition in estrogen positive MCF-7 cell line. Toxicol. Vitro 2019, 59, 150-160.
[32]
Musgrove, E. A.; Caldon, C. E.; Barraclough, J.; Stone, A.; Sutherland, R. L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11, 558-572.
[33]
Katunarić, M.; Jurišić, D.; Petković, M.; Grahovac, M.; Grahovac, B.; Zamolo, G. EGFR and cyclin D1 in nodular melanoma: Correlation with pathohistological parameters and overall survival. Melanoma Res. 2014, 24, 584-591.
[34]
Müller, D. W.; Bosserhoff, A. K. Integrin β3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008, 27, 6698-6706.
[35]
Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723.
[36]
Chen, X. J.; Deng, C. S.; Tang, S. L.; Zhang, M. Mitochondria-dependent apoptosis induced by nanoscale hydroxyapatite in human gastric cancer SGC-7901 cells. Biol. Pharm. Bull. 2007, 30, 128-132.
[37]
Chu, S. H.; Feng, D. F.; Ma, Y. B.; Li, Z. Q. Hydroxyapatite nanoparticles inhibit the growth of human glioma cells in vitro and in vivo. Int. J. Nanomedicine 2012, 7, 3659-3666.
[38]
Sun, Y.; Chen, Y. Y.; Ma, X. Y.; Yuan, Y.; Liu, C. S.; Kohn, J.; Qian, J. C. Mitochondria-targeted hydroxyapatite nanoparticles for selective growth inhibition of lung cancer in vitro and in vivo. ACS Appl. Mater. Interfaces 2016, 8, 25680-25690.
[39]
Lotfian, H.; Nemati, F. Cytotoxic effect of TiO2 nanoparticles on breast cancer cell line (MCF-7). IIOAB J. 2016, 7, 219-224.
[40]
Han, Y. C.; Wang, X. Y.; Dai, H. L.; Li, S. P. Nanosize and surface charge effects of hydroxyapatite nanoparticles on red blood cell suspensions. ACS Appl. Mater. Interfaces 2012, 4, 4616-4622.
[41]
Jordan, A.; Scholz, R.; Wust, P.; Schirra, H.; Schiestel, T.; Schmidt, H.; Felix, R. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J. Magn. Magn. Mater. 1999, 194, 185-196.
[42]
Navarro-Requena, C.; Pérez-Amodio, S.; Castaño, O.; Engel, E. Wound healing-promoting effects stimulated by extracellular calcium and calcium-releasing nanoparticles on dermal fibroblasts. Nanotechnology 2018, 29, 395102.
[43]
Li, Y.; Tan, B. B.; Zhao, Q.; Fan, L. Q.; Wang, D.; Liu, Y. ZNF139 promotes tumor metastasis by increasing migration and invasion in human gastric cancer cells. Neoplasma 2014, 61, 291-298.
[44]
Elkin, M.; Ariel, I.; Miao, H. Q.; Nagler, A.; Pines, M.; De-Groot, N.; Hochberg, A.; Vlodavsky, I. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res. 1999, 59, 4111-4118.
[45]
Qian, Q.; Wang, Q.; Zhan, P.; Peng, L.; Wei, S. Z.; Shi, Y.; Song, Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: A systematic review with meta-analysis. Cancer Invest. 2010, 28, 661-669.
[46]
Merchant, N.; Nagaraju, G. P.; Rajitha, B.; Lammata, S.; Jella, K. K.; Buchwald, Z. S.; Lakka, S. S.; Ali, A. N. Matrix metalloproteinases: Their functional role in lung cancer. Carcinogenesis 2017, 38, 766-780.
[47]
Marusak, C.; Bayles, I.; Ma, J.; Gooyit, M.; Gao, M.; Chang, M.; Bedogni, B. The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic dissemination. Pharmacol. Res. 2016, 113, 515-520.
[48]
Jiao, Y.; Feng, X.; Zhan, Y. P.; Wang, R. F.; Zheng, S.; Liu, W. G.; Zeng, X. L. Matrix metalloproteinase-2 promotes αvβ3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin. PLoS One. 2012, 7, e41591.
[49]
Sato, H.; Takino, T.; Okada, Y.; Cao, J.; Shinagawa, A.; Yamamoto, E.; Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994, 370, 61-65.
[50]
Moro, N.; Mauch, C.; Zigrino, P. Metalloproteinases in melanoma. Eur. J. Cell Biol. 2014, 93, 23-29.
[51]
Kurschat, P.; Wickenhauser, C.; Groth, W.; Krieg, T.; Mauch, C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J. Pathol. 2002, 197, 179-187.
[52]
Itoh, Y. MT1-MMP: A key regulator of cell migration in tissue. IUBMB Life. 2006, 58, 589-596.
[53]
Lydolph, M. C.; Morgan-Fisher, M.; Høye, A. M.; Couchman, J. R.; Wewer, U. M.; Yoneda, A. α9β1 integrin in melanoma cells can signal different adhesion states for migration and anchorage. Exp. Cell Res. 2009, 315, 3312-3324.
[54]
Zhang, J.; Na, S. J.; Liu, C. Y.; Pan, S. T.; Cai, J. Y.; Qiu, J. X. MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma. Tumor Biol. 2016, 37, 5941-5949.
[55]
Li, X. L.; Liu, L.; Li, D. D.; He, Y. P.; Guo, L. H.; Sun, L. P.; Liu, L. N.; Xu, H. X.; Zhang, X. P. Integrin β4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. Sci. Rep. 2017, 7, 40464.
[56]
Zhou, X. Y.; Murphy, F. R.; Gehdu, N.; Zhang, J. L.; Iredale, J. P.; Benyon, R. C. Engagement of αvβ3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J. Biol. Chem. 2004, 279, 23996-24006.
[57]
Gilbert, M.; Giachelli, C. M.; Stayton, P. S. Biomimetic peptides that engage specific integrin-dependent signaling pathways and bind to calcium phosphate surfaces. J. Biomed. Mater. Res. A 2003, 67A, 67-77.
[58]
Zhao, R.; Chen, S. Y.; Yuan, B.; Chen, X. N.; Yang, X.; Song, Y. M.; Tang, H.; Yang, X.; Zhu, X. D.; Zhang, X. D. Healing of osteoporotic bone defects by micro-/nano-structured calcium phosphate bioceramics. Nanoscale 2019, 11, 2721-2732.
[59]
Lin, J.; Yang, Q. Y.; Wilder, P. T.; Carrier, F.; Weber, D. J. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J. Biol. Chem. 2010, 285, 27487-27498.
[60]
Harpio, R.; Einarsson, R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem. 2004, 37, 512-518.
[61]
Salama, I.; Malone, P. S.; Mihaimeed, F.; Jones, J. L. A review of the S100 proteins in cancer. Eur. J. Surg. Oncol. 2008, 34, 357-364.
[62]
Pujari-Palmer, S.; Chen, S.; Rubino, S.; Weng, H.; Xia, W.; Engqvist, H.; Tang, L. P.; Ott, M. K. In vivo and in vitro evaluation of hydroxyapatite nanoparticle morphology on the acute inflammatory response. Biomaterials 2016, 90, 1-11.